E. Phillips
University of Cambridge
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by E. Phillips.
International Journal of Cancer | 1999
Max Partridge; G. Emilion; Stelios Pateromichelakis; E. Phillips; J.D. Langdon
To help define the location of tumour suppressor genes implicated in the pathogenesis of oral squamous cell carcinoma (SCC), we have used microsatellite assay and restriction fragment length polymorphism (RFLP) analysis to screen 48 primary SCC for allelic imbalance (AI) with 32 polymorphic markers at chromosome 3p, and prepared a detailed deletion map. The finding of a high frequency of AI at specific regions, together with the presence of multiple small interstitial deletions involving these loci, identifies 5 areas at this chromosome arm that may harbour tumour suppressor genes. No sequence aberrations affecting the von Hippel Lindau (VHL) and fragile histidine triad (FHIT) genes, which reside within the candidate tumour suppressor gene areas at this chromosome arm, were identified. A more limited analysis of polymorphic sequences at 8p and 9p supports the existence of at least 2 areas that harbour tumour suppressor genes at 8p and evidence that additional targets for deletion reside centromeric and telomeric to the p16 gene at 9p21. Int. J. Cancer 83:318–325, 1999.
The Journal of Pathology | 1999
Max Partridge; E. Phillips; R. Francis; S.-R. Li
Screening for malignant cells in the blood and bone marrow was introduced as a strategy for the improved detection of tumour spread and may predict the development of distant metastases. The sensitivity of these approaches depends on several factors, including the choice of antibody for immunocytochemistry (ICC) and the number of cells examined. In this study criteria have been defined for scoring cells reactive with a pan‐cytokeratin antibody as tumour, by comparing immunostained cells in clinical samples obtained from head and neck cancer patients and a control group without epithelial malignancy. When leucocyte subfractions are prepared by density gradient separation (DGS) from central venous blood obtained from patients with advanced head and neck squamous cell carcinoma (SCC) and screened by ICC, epithelial tumour cells sediment preferentially with the mononuclear cells but may also be detected in the granulocyte (GC) fraction. Some cases were found to have more tumour cells in the GC fraction. Similar results were seen in model experiments. To increase the sensitivity of the ICC approach, the efficiency of positive immunomagnetic selection (IMS) using Dynabeads coated with an antibody recognizing the Ber‐EP4 epitope has been compared with negative IMS using anti‐CD45 Dynabeads. Tumour cells were recovered from bone marrow aspirates for 2/17 cases using the positive enrichment technique and for 11/17 patients following negative IMS. These findings justify prospective studies incorporating negative IMS to establish the prognostic significance of these disseminated tumour cells for this group of patients. Copyright
Cancer Research | 2000
Max Partridge; Stylianos Pateromichelakis; E. Phillips; G. Emilion; R P A'Hern; J D Langdon
Clinical Cancer Research | 2000
Max Partridge; Shu-Rui Li; Stelios Pateromichelakis; Rebecca Francis; E. Phillips; Xiaohong Huang; Fis Tesfa-Selase; John Langdon
Oral Oncology | 1997
Max Partridge; G. Emilion; Stelios Pateromichelakis; E. Phillips; J.D. Langdon
Clinical Cancer Research | 2003
Max Partridge; Ruud H. Brakenhoff; E. Phillips; Kulsan Ali; Rebecca Francis; Richard Hooper; K.M. Lavery; A.E. Brown; John Langdon
Clinical Cancer Research | 2001
Max Partridge; Stelios Pateromichelakis; E. Phillips; Gracy Emilion; John Langdon
Oral Oncology | 2005
Stelios Pateromichelakis; Mosavar Farahani; E. Phillips; Max Partridge
Clinical Cancer Research | 2002
Roth Oakley; E. Phillips; Richard Hooper; Deborah Wilson; Max Partridge
Journal of Dental Research | 2004
Stylianos Pateromichelakis; M Farahani; E. Phillips; Max Partridge